Sims, Karen D <br/><br/>
Randomized, placebo-controlled, single-ascending-dose study of BMS-791325, a hepatitis C virus (HCV) NS5B polymerase inhibitor, in HCV genotype 1 infection.  [electronic resource] 

 -  Antimicrobial agents and chemotherapy  Jun 2014 
 - 3496-503 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1098-6596 
<br/><br/><label>Standard No.: </label>10.1128/AAC.02579-13  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antiviral Agents--administration & dosage<br/>Benzazepines--administration & dosage<br/>Cohort Studies<br/>Double-Blind Method<br/>Drug Resistance, Viral<br/>Female<br/>Genotype<br/>Half-Life<br/>Hepacivirus--classification<br/>Hepatitis C--drug therapy<br/>Humans<br/>Indoles--administration & dosage<br/>Interferons<br/>Male<br/>Middle Aged<br/>Phenotype<br/>RNA, Viral--blood<br/>RNA-Dependent RNA Polymerase--antagonists & inhibitors<br/>Viral Nonstructural Proteins--antagonists & inhibitors<br/>Young Adult